DelveInsight’s “Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and market size of the CMV for theglobal, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMVfrom 2013-2023. According to DelveInsight, the Global Diagnosed cases for Cytomegalovirus (CMV) Infection are expected to increase at a CAGR of 0.047% to 172,864 cases in 2023. Cytomegalovirus (CMV) infection is caused by Cytomegalovirus (CMV), a member of the herpes virus family. Upon initial infection, CMV infects the epithelial cells of the salivary gland, resulting in a persistent infection and viral shedding. Person can be infected with CMV at any point of time in life and is not easily diagnosed as no symptoms are shown.
As per DelveInsight’s estimation, the global market size of Cytomegalovirus (CMV) infection shall reach to USD 1,210.4 Million by the end of 2023. The market size for Prophylaxis is expected to grow at a CAGR 6.57% from 2013-2023, while the sales for the therapeutic shall increase at a CAGR of 3.44% from the 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Cytomegalovirus (CMV) infection for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
'
Cytomegalovirus Infections
Disease Overview
Symptoms of cytomegalovirus (CMV) Infection
Etiology
Risk Factors
Pathogenesis of human cytomegalovirus
Pathophysiology of cytomegalovirus infection
Diagnosis
Treatment Algorithm for Cytomegalovirus Infections
Treatment for Congenital CMV Infection
Treatment of Ganciclovir resistant CMV
Treatment Guidelines
Recommendations for Treating Cytomegalovirus Infections
Disease Management
Epidemiology and Patient Population
Global
Global CMV Prevalent, Diagnosed and Treatable Cases
United States
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Europe
Italy
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Spain
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
United Kingdom
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Germany
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
France
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Japan
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infant Patients at High Risk of CMV
HIV Patients at High Risk of CMV in Japan
Unmet Medical Needs
Marketed Products
Valcyte (Valganciclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
FOSCAVIR (foscarnet sodium)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoTect CP
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Valtrex (Valacyclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Emerging Products Analysis
Emerging Therapies
1. Approved Products
Cytovir CMV: Cell Medica Ltd.
Product Description
Research and Development
Product Development Activities
2. Pipeline Products (Phase III)
CytoTect CP 70: Biotest AG.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Letermovir: Merck & Co.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Brincidofovir: Chimerix Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
ASP0113: Astellas Pharma Global Development, Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Human Cytomegalovirus Immune Globulin: CSL Behring
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Global Market Size
United States
Europe
Italy
Germany
France
Spain
United Kingdom
Japan
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases (2013-2023)
Table 2: Total CMV Prevalent, Diagnosed and Treatable Cases for United States (2013-2023)
Table 3: CMV Patients among Transplants in United States (2013-2023)
Table 4: Infants Patients at High Risk of CMV in United States (2013-2023)
Table 5: HIV Patients at High Risk of CMV in United States (2013-2023)
Table 6 Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
Table 7: CMV Patients among Transplants in Italy (2013-2023)
Table 8: Infants Patients at High Risk of CMV in Italy (2013-2023)
Table 9: HIV Patients at High Risk of CMV in Italy (2013-2023)
Table 10: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
Table 11: CMV Patients among Transplants in Spain (2013-2023)
Table 12: Infants Patients at High Risk of CMV in Spain (2013-2023)
Table 13: HIV Patients at High Risk of CMV in Spain (2013-2023)
Table 14: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
Table 15: CMV Patients among Transplants in United Kingdom (2013-2023)
Table 16: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 17: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 18: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
Table 19: CMV Patients among Transplants in Germany (2013-2023)
Table 20: Infants Patients at High Risk of CMV in Germany (2013-2023)
Table 21: HIV Patients at High Risk of CMV in Germany (2013-2023)
Table 22: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
Table 23: CMV Patients among Transplants in France (2013-2023)
Table 24: Infants Patients at High Risk of CMV in France (2013-2023)
Table 25: HIV Patients at High Risk of CMV in France (2013-2023)
Table 26: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan (2013-2023)
Table 27: CMV Patients among Transplants in Japan (2013-2023)
Table 28: Infants Patients at High Risk of CMV in Japan (2013-2023)
Table 29: HIV Patients at High Risk of CMV in Japan (2013-2023)
Table 30: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 31: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 32: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 33: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 34: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 35: Total Market size of Cytomegalovirus (CMV) Infection USD, Million (2013-2023)
Table 36: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 37: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
